Besides the biological heterogeneity, there are technical challenges such as standardization/validation of IHC and ISH techniques across histologies, lack of guidelines regarding interpretation of HER2 IHC in histologies other than breast and gastric cancer, and an increase in turnaround time (TAT) with increasing case burden on technicians and pathologists. This evidence concerns the gene ERBB2 and gastric cancer.